Saturday 17 October 2026
Export SEELQ’s income statement to Excel — free account
Seelos Therapeutics, Inc.
SEELQ Healthcare Biotechnology
Seelos Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $2.2 million. Revenue growth for three consecutive years, operating cash flow growth for three.
0.00
0.00
NaN
Follow SEELQ
| Jun '24 | Mar '24 | Dec '23 | Sep '23 | Older periods | |
|---|---|---|---|---|---|
| (10.86%) | 100.87% | 171.72% | 453.43% |
+8 more TTM periods Free account |
|
| 57.34% | (198.99%) | (269.01%) | (218.66%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(14.52%) | 81.76% | 113.00% | 175.32% | |
Average Days of Receivables |
34.07 | 178.99 | 126.42 | 41.90 | |
Free Cash Flow per Share |
(84.76) | (179.19) | (624.33) | (996.90) | |
Free Cash Flow |
(13.27) | (18.21) | (23.91) | (35.09) | |
| Other line items | |||||
Cash ROIC |
47.68% | 55.88% | 78.36% | 132.29% | |
Accounts Receivable Turnover |
6.51 | 2.24 | 3.80 | 4.24 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.01 | |
Inventory Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 35,808.42 | |
Days of Inventory on Hand |
— | — | — | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,014.45% | 1,417.12% | 1,367.09% | 2,062.55% | |
Selling, General and Administrative Expense of Revenue |
565.59% | 588.75% | 571.27% | 654.08% | |
Share Based Compensation of Revenue |
186.94% | 196.61% | 181.03% | 204.21% | |
Interest Coverage |
(278.58) | (413.43) | (539.99) | (329.51) | |
Operating CF/Net income |
(3.24) | 0.67 | 0.63 | 0.69 | |
Depreciation/Fixed assets |
0.00 | 0.00 | — | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | — | 0.00 | |
Revenue per Share |
12.86 | 19.43 | 57.52 | 54.69 | |
Operating CF per Share |
(84.76) | (179.19) | (624.33) | (996.90) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates